BioMedNewsBreaks Archive - Page 77 of 276

ThursdayDec 12, 2024 12:04 pm

BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Secures $1M Premium Equity Funding to Advance Age-Reversal Therapies

Telomir Pharmaceuticals (NASDAQ: TELO) has raised $1 million in equity funding from The Starwood Trust through a common stock transaction priced at $7 per share, a 20% premium to the closing price. This follows an undrawn $5 million non-dilutive line of credit from The Starwood Trust earlier this year, reinforcing confidence in Telomir’s strategy. The funding supports Telomir’s innovative pipeline, led by its breakthrough compound, Telomir-1, which has demonstrated preclinical efficacy in reversing age-related conditions, including Type 2 diabetes, by addressing root causes like oxidative stress and telomere shortening. Telomir is also advancing research in Alzheimer’s, cancer, osteoarthritis, and Wilson…

WednesdayDec 11, 2024 2:02 pm

BioMedNewsBreaks — Astiva Health Eyes Continued Momentum on Heels of Remarkable Growth

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, anticipates strong growth in membership in 2025. The momentum is expected to build upon the record-setting performance already achieved this year in terms of network and membership expansion. “According to a company news release, membership is expected to grow by 70% or 7,000 members, a major increase from the numbers reported this year. Astiva Health started off with a membership jump in January 2024, when it reached 10,000 members (22% higher than the 3,100 members recorded in January 2023), and then again…

WednesdayDec 11, 2024 8:45 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Secures Three-Year State Government Contract for Outfitter Satellite Connectivity Services

NextPlat (NASDAQ: NXPL, NXPLW) announced that its U.S.-based connectivity division, Outfitter Satellite Inc., has been awarded a three-year contract by a U.S. state government to provide satellite connectivity services. The agreement includes satellite airtime service plans and hardware to support the government workforce during remote operations and natural disasters, with an option to extend for two additional years. Outfitter, acquired by NextPlat in April 2024, has over two decades of experience delivering satellite-based connectivity solutions and has generated significant recurring revenue from its services across North America. David Phipps, President of NextPlat, highlighted Outfitter’s role in driving domestic growth and its…

TuesdayDec 10, 2024 2:40 pm

BioMedNewsBreaks — Adageis Engages IBN for Corporate Communications Expertise

Adageis is a healthcare technology company dedicated to revolutionizing patient care through innovative value-based care solutions. Through integrating artificial intelligence (“AI”) and machine learning, Adageis’ Patented Risk Engine (“PRE”) transforms healthcare delivery, equipping providers with tools to enable value-based care, improve patient outcomes, and increase operational efficiency. The company’s flagship ProActive Care Platform integrates with existing electronic medical records (“EMR”) systems, offering a seamless, AI-powered solution. Adageis has selected IBN, a multifaceted financial news and publishing company for private and public entities, to spearhead its corporate communications efforts. As part of the client partner relationship, IBN will generate greater…

TuesdayDec 10, 2024 1:40 pm

BioMedNewsBreaks – BioAdaptives Inc. (BDPT) Launches Xcellara(TM) — an Innovative Supplement That Harnesses Nature for Optimal Health

BioAdaptives (OTC: BDPT) today announced the launch of Xcellara(TM) Stem Cell Activator, a groundbreaking supplement that harnesses the extraordinary potential of stem cells' regeneration power through a blend of adaptogens, herbs and beneficial bacteria. The innovative formulation supports the body's natural repair mechanisms, promoting anti-aging and enhancing overall health and wellness. "This is an exciting milestone for BioAdaptives as we continue to push the boundaries of what's possible in natural health supplements," said the company’s CEO James Keener. "With the launch of Xcellara(TM) Stem Cell Activator, we're offering a product that's both innovative and deeply rooted in science, leveraging a…

TuesdayDec 10, 2024 12:33 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Advances CNM-Au8 in ALS with FDA Guidance on Accelerated Approval Pathway

Clene (NASDAQ: CLNN) received FDA guidance on leveraging data from its ongoing expanded access programs (“EAPs”) to support an accelerated approval application for CNM-Au8, its treatment for ALS. The FDA recommended using neurofilament light chain (“NfL”) biomarker analyses to substantiate the drug’s efficacy. Clene plans to submit additional data in mid-2025, alongside commencing the Phase 3 RESTORE-ALS trial. Clinical findings presented at an FDA meeting highlighted CNM-Au8’s significant survival benefits and benign safety profile, underscoring its potential as a transformative ALS therapy. Clene remains committed to addressing the urgent unmet needs of ALS patients. To view the full press release, visit https://ibn.fm/xFrwd…

TuesdayDec 10, 2024 10:44 am

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Expands e-Commerce Presence in China Through JD.com Partnership

NextPlat (NASDAQ: NXPL, NXPLW) has secured vendor approval from JD.com, China’s largest self-operated e-Commerce retailer, to sell OPKO Health Europe’s branded health, wellness, and veterinary products. Under an exclusive agreement with OPKO Health Europe, NextPlat will begin listing nutraceutical products for bone and joint health, nutrition, and immunity on JD.com in early 2025, with plans to expand offerings to include innovative veterinary care products pending regulatory clearance. Leveraging JD.com’s platform, which serves over 560 million annual users, this initiative aligns with the growing demand for premium healthcare products in China, where the nutraceutical market is projected to reach $100…

MondayDec 09, 2024 1:34 pm

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Projects Over 70% Revenue Growth for 2024, Driven by Key Business Segments

NextPlat (NASDAQ: NXPL, NXPLW) anticipates reporting approximately $63 million in annual revenue for 2024, reflecting a more than 70% increase from fiscal 2023 results, subject to final accounting and auditing. The significant growth is attributed to strong performance in satellite connectivity products, high-margin recurring airtime revenue, and contributions from the healthcare business. The company plans to file its 2024 annual report by March 31, 2025, and host an earnings conference call with investors. To view the full press release, visit: https://ibn.fm/CeHlA About NextPlat Corp NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets…

ThursdayDec 05, 2024 2:57 pm

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Strategic Board Appointment

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in the development of inflammation and immunology (“I&I”) biological products and offering CDMO services through its Scinai Bioservices unit, today announced the appointment of Prof. Michael Schön to its Scientific Advisory Board (“SAB”). Recognized with numerous awards for his groundbreaking research on immune reactions in inflammation, Prof. Michael Schön is a distinguished professor and director of the Department of Dermatology, Venereology and Allergology at the University Medical Center Göttingen. He also serves as vice dean and deputy director for research and teaching and is the former director of the Lower Saxony Institute…

ThursdayDec 05, 2024 2:47 pm

BioMedNewsBreaks — Branded Legacy Inc. (BLEG) Reaffirms Commitment to Growth and Innovation in Biotech, Wellness Sectors

Branded Legacy (OTC: BLEG) today announced updates as it confronts recent challenges and charts a focused path forward. In the announcement, the company reaffirmed its commitment to the biotech and wellness sectors, with its primary focus on expanding its wholly owned subsidiary, Sycamore BioPharma. “These challenges have only strengthened our resolve,” stated Branded Legacy CEO Dave Oswald. “While the actions of former employees have created significant hurdles, our commitment to growth and innovation remains unwavering. By focusing on our more successful subsidiaries and securing the necessary funding to expand, we are poised to recover and achieve even greater success in…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Telomir Pharmaceuticals (NASDAQ: TELO) Secures $1M Premium Equity Funding to Advance Age-Reversal Therapies

BioMedNewsBreaks — Astiva Health Eyes Continued Momentum on Heels of Remarkable Growth

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Secures Three-Year State Government Contract for Outfitter Satellite Connectivity Services

BioMedNewsBreaks — Adageis Engages IBN for Corporate Communications Expertise

BioMedNewsBreaks – BioAdaptives Inc. (BDPT) Launches Xcellara(TM) — an Innovative Supplement That Harnesses Nature for Optimal Health

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Advances CNM-Au8 in ALS with FDA Guidance on Accelerated Approval Pathway

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Expands e-Commerce Presence in China Through JD.com Partnership

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Projects Over 70% Revenue Growth for 2024, Driven by Key Business Segments

BioMedNewsBreaks — Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Strategic Board Appointment

BioMedNewsBreaks — Branded Legacy Inc. (BLEG) Reaffirms Commitment to Growth and Innovation in Biotech, Wellness Sectors

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search